A new IA drug in OA 🚨 Cell therapy of apoptotic PBMCs ENX-CL-05-001 RCT Ph2A moderate to severe OA 134 pts 3 injections vs. PBO Pain improvement 24% Better response in people > 60 and more so 65yo Potential improvement for > 6mo Safety mainly local reactions to compound https://t.co/m2MZN3i22b

• https://x.com/AurelieRheumo/status/1983262445809311986/photo/1

Lung Ultrasound in CTD-ILD Prospective cohort 146 pts CTD-ILD 30 preclinical ILD 76 limited ILD 40 extensive ILD Median LUS scores higher if Extensive ILD LUS scores correlation w/ fibrosis severity, DLCO & FCV Agreement between LUS and HRCT severity 0.74 Excellent inter https://t.co/R9zGmCTT8Q

• https://x.com/AurelieRheumo/status/1983260820139098168/photo/1

Adverse events from avacopan the WHO pharmacovigilence database (VigiBase) Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz

• https://x.com/EBRheum/status/1983225627403563379/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.

EGPA relapse in MANDARA including OLE Majority of relapses are asthma / sinonasal in nature Of non-airway: - arthralgia/myalgia - sensory peripheral neuropathy @RheumNow #ACR25 Abst1769 https://t.co/cPjjzl4RWS

• https://x.com/Dr_Brian_MD/status/1983207993974853770/photo/1
• https://x.com/Dr_Brian_MD/status/1983207993974853770/photo/1

CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

• https://x.com/AkhilSoodMD/status/1983207128077873559/photo/1

IgG4-RD continues to present in new and unusual ways Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement RCA and LAD most affected Seen on CTA Majority received RTX 7/9 pt at least partially improved imaging on f/u @RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb

• https://x.com/Dr_Brian_MD/status/1983201652707602640/photo/1

RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck) Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪 @RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k

• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1

MSK side effects of CAR-T, based on FAERS pharmacovigilance data (also see @DrGomezPuerta in @seminarthrheum https://t.co/LnwjU5aebs) #ACR25 ABST1731 @RheumNow https://t.co/kREEy3HLE9

• https://www.sciencedirect.com/science/article/abs/pii/S0049017224002506
• https://x.com/drdavidliew/status/1983201000443072522/photo/1

Adding social risk factors to the mix Abstract 1917: WashU Rheumatology examined SRF screening in the clinic 🔹 50% screened once; 1/3 screened > 1 🔹 Core SRFs (finance, transport, housing, food) relatively stable 🔹 Biggest change over time: stress @RheumNow #ACR25 https://t.co/oKlwMZ77nB

• https://x.com/AkhilSoodMD/status/1983198823745749097/photo/1

Higashida-Konishi et al. RA. Insomnia and fatigue in >80%, depression in 13%. RA disease activity is associated with depression, fatigue, and insomnia. @RheumNow #ACR25 Abstr#2254 https://t.co/7SibPW6BBw

• https://x.com/RichardPAConway/status/1983197816815333851/photo/1

Hojiej et al. Prevalence and Impact of lifestyle factors in PsA. Lifestyle factors impacted disease activity. Cumulative effect of increasing number of factors @RheumNow #ACR25 Abstr#2309 https://t.co/oDGQyLBRDO

• https://x.com/RichardPAConway/status/1983195551920460244/photo/1

Macedo et al. Increasing exercise improved QoL in axSpA. Mobility limitation and obesity worsened it. At least to some degree these effects appear independent. @RheumNow #ACR25 Abstr#2326 https://t.co/Ei4cKTNHyn

• https://x.com/RichardPAConway/status/1983194545300099396/photo/1